Cargando…

Scriptaid overcomes hypoxia-induced cisplatin resistance in both wild-type and mutant p53 lung cancer cells

Non-small cell lung cancer (NSCLC), comprising 85% of lung cancer cases, has been associated with resistance to chemo/radiotherapy. The hypoxic tumor micro-environment, where insufficient vasculature results in poor drug penetrance and sub-optimal chemotherapy in the tumor interiors contributes heav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pradhan, Shrikant, Mahajan, Divyank, Kaur, Prabhjot, Pandey, Namita, Sharma, Chandresh, Srivastava, Tapasya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342127/ https://www.ncbi.nlm.nih.gov/pubmed/27708247 http://dx.doi.org/10.18632/oncotarget.12378

Ejemplares similares

The in vitro development of cloned sheep embryos treated with Scriptaid and Trichostatin (A)
por: Al-Ghadi, Muath Q, et al.
Publicado: (2020)

Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998)

Anticancer effect of histone deacetylase inhibitor scriptaid as a single agent for hepatocellular carcinoma
por: Liu, Linlin, et al.
Publicado: (2018)

Histone Deacetylase Inhibitor Scriptaid Alleviated Neurological Dysfunction after Experimental Intracerebral Hemorrhage in Mice
por: Yang, Heng, et al.
Publicado: (2018)

SNP rs9387478 at ROS1-DCBLD1 Locus is Significantly Associated with Lung Cancer Risk and Poor Survival in Indian Population
por: Chongtham, Jonita, et al.
Publicado: (2022)

HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity
por: Sharma, Vivek, et al.
Publicado: (2010)

SNP rs16969968 as a Strong Predictor of Nicotine Dependence and Lung Cancer Risk in a North Indian Population
por: Pandey, Namita, et al.
Publicado: (2017)

Direct Amidation to Access 3-Amido-1,8-Naphthalimides Including Fluorescent Scriptaid Analogues as HDAC Inhibitors
por: Hearn, Kyle N., et al.
Publicado: (2021)

Hypoxia-Induced Cisplatin Resistance in Non-Small Cell Lung Cancer Cells Is Mediated by HIF-1α and Mutant p53 and Can Be Overcome by Induction of Oxidative Stress
por: Deben, Christophe, et al.
Publicado: (2018)

Overcoming hypoxia-induced chemoresistance to cisplatin through tumor oxygenation monitored by optical imaging
por: Song, Donghui, et al.
Publicado: (2019)

Single-cell assessment of transcriptome alterations induced by Scriptaid in early differentiated human haematopoietic progenitors during ex vivo expansion
por: Hua, Peng, et al.
Publicado: (2019)

Scriptaid Treatment Decreases DNA Methyltransferase 1 Expression by Induction of MicroRNA-152 Expression in Porcine Somatic Cell Nuclear Transfer Embryos
por: Liang, Shuang, et al.
Publicado: (2015)

Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a “dominant-positive” mechanism
por: Walerych, Dawid, et al.
Publicado: (2018)

Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins
por: Bruno, Tiziana, et al.
Publicado: (2016)

Aberrant methylation and associated transcriptional mobilization of Alu elements contributes to genomic instability in hypoxia
por: Pal, Arnab, et al.
Publicado: (2010)

Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tum3or cells
por: Bhatt, Michelle, et al.
Publicado: (2016)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

Targeting Hypoxia Sensitizes TNBC to Cisplatin and Promotes Inhibition of Both Bulk and Cancer Stem Cells
por: Sulaiman, Andrew, et al.
Publicado: (2020)

The HDAC Inhibitors Scriptaid and LBH589 Combined with the Oncolytic Virus Delta24-RGD Exert Enhanced Anti-Tumor Efficacy in Patient-Derived Glioblastoma Cells
por: Berghauser Pont, Lotte M.E., et al.
Publicado: (2015)

Mithramycin and Analogs for Overcoming Cisplatin Resistance in Ovarian Cancer
por: Schweer, David, et al.
Publicado: (2021)

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer
por: Shi, Zhen-duo, et al.
Publicado: (2022)

Retinoblastoma protein-initiated cellular growth arrest overcomes the ability of cotransfected wild-type p53 to induce apoptosis
por: Shinohara, H, et al.
Publicado: (2000)

Scutellarin Increases Cisplatin-Induced Apoptosis and Autophagy to Overcome Cisplatin Resistance in Non-small Cell Lung Cancer via ERK/p53 and c-met/AKT Signaling Pathways
por: Sun, Chao-Yue, et al.
Publicado: (2018)

Mir‐1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53
por: Wang, Xinyan, et al.
Publicado: (2018)

TIPE1 Promotes Cervical Cancer Cell Chemoresistance to Cisplatin in a Wild-Type p53-Dependent Manner
por: Jiang, Jie, et al.
Publicado: (2021)

Overcoming cisplatin resistance by mTOR inhibitor in lung cancer
por: Wu, Chunjing, et al.
Publicado: (2005)

Disulfiram Overcomes Cisplatin Resistance in Human Embryonal Carcinoma Cells
por: Schmidtova, Silvia, et al.
Publicado: (2019)

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer
por: Huang, Linjuan, et al.
Publicado: (2023)

Nanoparticle-Mediated Delivery of Satraplatin to Overcome Cisplatin Drug Resistance
por: Jiang, Xiaohan, et al.
Publicado: (2023)

Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways
por: Chiang, Kun-Chun, et al.
Publicado: (2014)

Valproic acid overcomes hypoxia-induced resistance to apoptosis
por: CIPRO, ŠIMON, et al.
Publicado: (2011)

Hyperthermia: The Optimal Treatment to Overcome Radiation Resistant Hypoxia
por: Elming, Pernille B., et al.
Publicado: (2019)

Overcoming hypoxia-induced functional suppression of NK cells
por: Solocinski, Kristen, et al.
Publicado: (2020)

Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells
por: García-Garrido, Eduardo, et al.
Publicado: (2021)

PP2A inhibition with LB100 enhances cisplatin cytotoxicity and overcomes cisplatin resistance in medulloblastoma cells
por: Ho, Winson S., et al.
Publicado: (2016)

APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
por: Mohell, N, et al.
Publicado: (2015)

DNA damage is overcome by TRIP13 overexpression during cisplatin nephrotoxicity
por: Hama, Taketsugu, et al.
Publicado: (2021)

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer
por: Rajendran, Ganeshkumar, et al.
Publicado: (2021)

Health Benefits of Modificated Multiplatinum Derivatives as Strategies for Overcoming the Cisplatin Resistance
por: Ivanova, Stefka Achkova, et al.
Publicado: (2023)

Regulation of glucose and glutamine metabolism to overcome cisplatin resistance in intrahepatic cholangiocarcinoma
por: Yang, So Mi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_220rgpjp1n8ttb6d30jjcd3o8r